Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1385 articles by Jacob Bell
-
A Versant-backed biotech emerges to take on ‘overlooked’ cancer targets
Oct. 6, 2022 -
Biogen, Denali begin late-stage testing of Parkinson’s drug
Oct. 3, 2022 -
5 FDA decisions to watch in the fourth quarter
Oct. 3, 2022 -
Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost
Sept. 30, 2022 -
ALS drug approved by FDA in closely watched decision, marking win for patients, developer
Sept. 29, 2022 -
With little data to go on, experts question how useful Eisai, Biogen’s new Alzheimer’s drug will be
Sept. 29, 2022 -
Vertex given green light to seek US approval of CRISPR-based therapy
Sept. 27, 2022 -
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
Sept. 26, 2022 -
FDA advisers back Amylyx ALS drug, reversing earlier position
Sept. 7, 2022 -
Neurocrine, with latest deal, gets a foothold in Europe
Aug. 30, 2022 -
Incyte secures second approval for targeted cancer drug
Aug. 29, 2022 -
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
Aug. 25, 2022 -
Backed by $40M, a biotech startup targets cancer with help from the immune system
Aug. 25, 2022 -
Next-generation RNA technologies: making longer-lasting drugs with a broader reach
Aug. 23, 2022 -
Gilead, with new results, doubles down on breast cancer drug
Aug. 16, 2022 -
Despite failed trial, Brainstorm asks FDA to approve ALS drug
Aug. 15, 2022 -
Karuna shares soar on schizophrenia drug results
Aug. 8, 2022 -
Amgen bets almost $4B on a biotech and its inflammation drugs
Aug. 4, 2022 -
Gilead, following cell therapy approval, impresses Wall Street with fast sales
Aug. 3, 2022 -
AbbVie, targeting a well-known protein family, expands a partnership into neuroscience
Aug. 2, 2022 -
Nuvation to cut workforce by 35% as it scraps lead drug program
Aug. 1, 2022 -
Novartis-linked startup launches with technology designed to remove ‘destroy’ tags on helpful proteins
July 28, 2022 -
FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug
July 26, 2022 -
With Aduhelm sidelined, Wall Street turns to Biogen's next Alzheimer's drug
July 20, 2022 -
FDA approves new vitiligo treatment, bolstering Incyte's dermatology business
July 19, 2022